Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials [7]

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 6, 2007, Pages 1411-1413

  Poveda, Eva ^a   Vispo, Eugenia ^a   Pattery, Theresa ^b   De Mendoza, Carmen ^a   Villacian, Jorge ^b   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Virco BVBA   (Belgium)

Author keywords

Drug resistance; HIV; Virological response

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; CD4 ANTIGEN; DARUNAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; GLYCINE; ISOLEUCINE; LAMIVUDINE; LEUCINE; LOPINAVIR; METHIONINE; PHENYLALANINE; PROTEINASE; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA POLYMERASE; SERINE; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VALINE; VIRUS ENVELOPE PROTEIN; VIRUS RNA; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LYMPHOCYTE COUNT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; SEQUENCE ANALYSIS; SPAIN; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 36448983198     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm367     Document Type: Letter

References (5)

1. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78.
2. De Meyer S, Vangeneugden T, Lefebvre E et al. Phenotypic and genotypic determinants of resistance to TMC114: Pooled analysis of POWER 1, 2 and 3. In: Abstracts of the Fifteenth International HIV Drug Resistance Workshop, Sitges, Spain, 2006. Abstract 73.
3. Johnson V, Brun-Vézinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14: 125-30.
4. Hertogs K, de Bethune M, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-76.
5. Cohen C, Falcon R, Rinehart A et al. Factors influencing darunavir/r efficacy in treatment-experienced HIV patients. POWER 1, 2 and 3 pooled 48-week analysis. In: Abstracts of the Forty-fourth IDSA, Toronto, Canada, 2006. Abstract P688.